N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces two operational updates.
N4 Pharma PLC (AIM:N4P) siRNA update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing
N4 Pharma’s share price has risen due to positive developments related to Nuvec
N4 Pharma PLC’s (AIM: N4P) shares have risen by more than 7% following the biotech firm’s announcement that it has successfully completed the single loading of EGFR and BCL-2 siRNA
N4 Pharma PLC (AIM:N4P) Double siRNA Testing Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec®
N4 Pharma PLC (AIM:N4P) Operational Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an operational update on its development
N4 Pharma PLC (AIM:N4P) Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce a further update on its recent
N4 Pharma PLC (AIM:N4P) Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce an update on its current work
N4 Pharma PLC (AIM: N4P) Final Results
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce its audited results for the year
Nigel Theobald, Chief Executive Officer N4 Pharma PLC (LON:N4P) Interview
N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive
Yourgene Health PLC (YGEN.L) DHSC contract award for COVID Winter surge testing
Third contract awarded under PHE National Microbiology Framework Agreement
Poolbeg Pharma PLC (POLB.L) PredictViral™ Patent update
14 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new